---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-22-018776"
form_type: "8-K"
ticker: "SNGX"
cik: "0000812796"
company_name: "SOLIGENIX, INC."
filed_at: "2022-12-19T23:59:59+00:00"
generated_at: "2026-06-21T02:57:56.282658+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Soligenix opens enrollment in Phase 2a trial of SGX302 for mild-to-moderate psoriasis

## Summary
- Phase 2a study (HPN-PSR-01) initiating enrollment of up to 42 patients with mild-to-moderate psoriasis.
- Part A open-label (5-10 patients) followed by Part B double-blind 1:1 active vs. placebo for 18 weeks treatment plus 4-week follow-up.
- SGX302 (synthetic hypericin) activated by visible light; efficacy endpoints include lesion clearance and quality of life.
- Psoriasis affects ~7.5M people in U.S. and 60-125M worldwide; Soligenix estimates >$1B global market for SGX302.
- SGX302 also under NDA review for cutaneous T-cell lymphoma (Phase 3 FLASH study).

## SEC filing metadata
- accession: 0001558370-22-018776
- form_type: 8-K
- ticker: SNGX
- cik: 0000812796
- company_name: SOLIGENIX, INC.
- filed_at: 2022-12-19T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/812796/000155837022018776/0001558370-22-018776-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/812796/000155837022018776/tmb-20221219x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-22-018776
- JSON: https://secwatch.observer/filing/0001558370-22-018776.json
- Plain text: https://secwatch.observer/filing/0001558370-22-018776.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.